%0 Journal Article
%T Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
%A Luis Arias
%A Jordi Mon¨¦s
%J Clinical Ophthalmology
%D 2010
%I 
%R http://dx.doi.org/10.2147/OPTH.S8635
%X ansconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration Original Research (4853) Total Article Views Authors: Luis Arias, Jordi Mon¨¦s Published Date February 2010 Volume 2010:4 Pages 67 - 72 DOI: http://dx.doi.org/10.2147/OPTH.S8635 Luis Arias1,2, Jordi Mon¨¦s1 1Institut de la M¨¤cula i de la Retina, Centro M¨¦dico Teknon, Barcelona; 2Hospital Universitari de Bellvitge, L¡¯Hospitalet de Llobregat, Barcelona Purpose: To determine the efficacy and safety of treating predominantly hemorrhagic age-related macular degeneration (AMD) with transconjunctival sutureless vitrectomy (TSV), tissue plasminogen activator (tPA), sulphur hexafluoride (SF6), and intravitreal bevacizumab. Methods: Retrospective study, consecutive case series. Patients with acute hemorrhagic AMD treated with 25- or 23-gauge TSV, subretinal or intravitreal tPA, fluid-air-SF6 exchange and intravitreal injection of bevacizumab. All operations were performed within the first 5 days after the start of symptoms, which consisted of visual acuity (VA) loss and central scotoma. Results: Fifteen eyes from 15 patients were included. The patients¡¯ mean age was 79.6 years, and the mean follow-up was 11.8 months. Five patients (33%) were receiving oral anticoagulant treatment. At baseline, the mean VA (logMAR values) was 1.5 (20/640 Snellen equivalent). At the last follow-up visit, the mean VA was 1.1 (20/250) (P < 0.0001; paired t-test). The submacular hemorrhage was successfully displaced in all the cases. Complications consisted of three cases of vitreous hemorrhage and a tear or the retinal pigment epithelium. Twelve cases (80%) did not require further treatment during the follow-up period. Conclusion: A surgical approach with 25- or 23-gauge TSV, tPA, SF6 and intravitreal bevacizumab is an efficacious and safe procedure in patients with hemorrhagic AMD. Early treatment is advisable for obtaining the optimal outcome.
%K Hemorrhagic age-related macular degeneration
%K tissue plasminogen activator
%K intravitreal bevacizumab
%K transconjunctival sutureless vitrectomy
%U https://www.dovepress.com/transconjunctival-sutureless-vitrectomy-with-tissue-plasminogen-activa-peer-reviewed-article-OPTH